Last updated on March 2019

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Brief description of study

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).

Clinical Study Identifier: NCT03614156

Contact Investigators or Research Sites near you

Start Over

Collaborative Neuroscience Network

Garden Grove, CA United States
  Connect »

Synergy Research San Diego

National City, CA United States
  Connect »

Excell Research Inc.

Oceanside, CA United States
  Connect »

NRC Research Institute

Orange, CA United States
  Connect »

Innova Clinical Trials

Miami, FL United States
  Connect »

iResearch Atlanta, LLC

Decatur, GA United States
  Connect »

Iris Research, Inc.

Smyrna, GA United States
  Connect »

Capstone Clinical Research

Libertyville, IL United States
  Connect »

Pharmasite Research, Inc.

Baltimore, MD United States
  Connect »

CBH Health, LLC

Gaithersburg, MD United States
  Connect »

Boston Clinical Trials

Boston, MA United States
  Connect »

Adams Clinical

Watertown, MA United States
  Connect »

Precise Research Centers

Flowood, MS United States
  Connect »

Altea Research Institute

Las Vegas, NV United States
  Connect »

Bioscience Research LLC

Mount Kisco, NY United States
  Connect »

Finger Lakes Clinical Research

Rochester, NY United States
  Connect »

IPS Research Company

Oklahoma City, OK United States
  Connect »

Keystone Clinical Studies, LLC

Norristown, PA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.